105,893 Shares in Roivant Sciences Ltd. $ROIV Purchased by Peak Financial Advisors LLC

Peak Financial Advisors LLC purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 105,893 shares of the company’s stock, valued at approximately $2,933,000. Roivant Sciences accounts for 1.3% of Peak Financial Advisors LLC’s holdings, making the stock its 23rd biggest position.

A number of other large investors have also added to or reduced their stakes in the stock. Fifth Third Wealth Advisors LLC boosted its stake in Roivant Sciences by 4.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after acquiring an additional 445 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after purchasing an additional 500 shares during the last quarter. Bank of Montreal Can grew its holdings in Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after purchasing an additional 516 shares during the period. Allworth Financial LP increased its position in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. Finally, Fifth Third Bancorp raised its stake in shares of Roivant Sciences by 15.8% in the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

ROIV opened at $34.07 on Monday. The stock has a market capitalization of $24.51 billion, a P/E ratio of -56.78 and a beta of 1.13. Roivant Sciences Ltd. has a 12-month low of $10.70 and a 12-month high of $34.68. The stock has a 50-day moving average price of $29.66 and a 200-day moving average price of $26.81.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The company had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. During the same quarter in the previous year, the company posted ($0.29) EPS. On average, equities research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Activity at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the sale, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 903,312 shares of company stock valued at $27,437,883. Insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.